Immatics Operating Margin from 2010 to 2024
| IMTX Stock | USD 7.59 0.01 0.13% |
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many indicators such as Price To Sales Ratio of 13.5, Dividend Yield of 0.0 or PTB Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules.
Immatics | Operating Margin |
Latest Immatics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Immatics NV over the last few years. It is Immatics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.42) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Immatics Operating Margin Regression Statistics
| Arithmetic Mean | (6.16) | |
| Geometric Mean | 4.27 | |
| Coefficient Of Variation | (61.88) | |
| Mean Deviation | 3.57 | |
| Median | (9.13) | |
| Standard Deviation | 3.81 | |
| Sample Variance | 14.51 | |
| Range | 9.3004 | |
| R-Value | 0.85 | |
| Mean Square Error | 4.43 | |
| R-Squared | 0.72 | |
| Significance | 0.000069 | |
| Slope | 0.72 | |
| Total Sum of Squares | 203.17 |
Immatics Operating Margin History
About Immatics Financial Statements
Immatics investors use historical fundamental indicators, such as Immatics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.